All
SBRT May Be Superior to Radiofrequency Ablation in Liver Cancer
SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less.
UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer
Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.
Cancer Vaccine Elicits Promising Responses in Renal Cell Carcinoma
All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.
The Good and The Bad of Follicular Lymphoma
My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring monitoring and follow-up.
An Expert Breaks Down the Effect of Diabetes on Urothelial Cancer Treatment
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or refractory multiple myeloma.
Learning to Live with Advanced Non-Small Cell Lung Cancer
Sponsored by Regeneron
Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma
Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.
Understanding the Distinction Between HER2-Low and HER2-Ultralow Breast Cancer
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC
Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.
Rediscovering My Sense of Faith Following a Colon Cancer Diagnosis
Faith, from my perspective, is believing in the unseen, and was something I rediscovered following my colon cancer diagnosis.
An Expert Explains The Risk and Outcomes of Primary Urothelial Cancer Treatment
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
mpMRI Improves Initial Staging in Suspected Muscle-Invasive Bladder Cancer
Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of bladder tumor was beneficial.
GAP Regimen May Not Improve Survival in Biliary Tract Cancer Subset
The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.
Treatment Intensification Adoption Differences Across Prostate Cancer
There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.
EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.
Outcomes May Be Consistent With Fotivda Alone or With Opdivo in Kidney Cancer Subset
Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.
Opdivo Plus Cabometyx Safe, Effective in Advanced Renal Cell Carcinoma
Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.
Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC
Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy.
Antitumor Activity Elicited in ccRCC Following Lenvima/Welireg Treatment
Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus Keytruda plus Lenvima.
FDA-Approved Fotivda Dose More Effective Than Reduced Dose in RCC
Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.
Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.
Padcev Significantly Improves OS in Real-World Urothelial Carcinoma
Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall survival outcomes.
Understanding How One Must Interpret PSA Levels in Prostate Cancer
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression.
Padcev Plus Keytruda Shows Promise for Upper Tract Urothelial Carcinoma Lesions
Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.
High Omega-3 Diet With Fish Oil Reduces Ki-67 Index in Prostate Cancer
Among patients with prostate cancer, a high omega-3, low-omega-6 diet with fish oil led to a Ki-67 index decrease.
Neuropathy, Rash, Hyperglycemia Linked to PFS in Urothelial Carcinoma
Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in metastatic urothelial carcinoma.
Padcev May Be Safe in Older Patients With Bladder Cancer
Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.
Are We at Risk of Losing Our Breast Cancer Community?
I found community after my metastatic breast cancer diagnosis, but recent discord in cancer support groups makes me fear we're losing these vital connections.
Estrogen Patches with ARPIs Found to Be Safe, Effective in Prostate Cancer
Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone analogues and ARPIs among patients with metastatic prostate cancer.
